Annexon (ANNX)
(Delayed Data from NSDQ)
$6.65 USD
-0.38 (-5.41%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $6.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Annexon, Inc. [ANNX]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
ANX007?s 12-Month Data Continues to Show Vision Protection, Positive for ARCHER
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Boots on the Ground at CTS 2024-New Innovations in the Retina
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
GBS Paves the Way for C1q as a Potent Target for Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Targeting C1q Differentiates ANX007?s Neuroprotective MOA from the Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
ANX005?s GBS Trial Design Superior to that of Eculizumab-Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Differentiated GBS Trial Design Encouraging for ANX005; Reiterate Buy and $30 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
ANX1502 and ANX007 Promises Differentiated Solution to Current SOCs, Rejuvenates Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
mEGOS, A Predictive Modeling Approach Aims to Improve GBS Phase 3 Trial Outcome
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Annexon Tests C1q?s Unique Role in Complement Driven Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
ANX007 Offers a Differentiated Approach in Preserving Vision-Reporting from the Emerald City
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Focusing on Protection from Vision Loss in GA is Unique-Thoughts on ARCHER
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Attacking C1q in GA Differentiates ARCHER; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Annexon?s GA Program; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Trial Design for ARCHER is Key to Evaluating C1q Hypothesis; Reit. Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Focus on the Upcoming Phase 2 WAIHA Data Readout in 2H2022; Reit. Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 HD Data Validates ANX005''s MOA and Opens Potential Pathway For a Confirmatory Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
What to Expect in the Upcoming WAIHA Data Readout in 2H2022; Reit Buy and Lower PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 HD Data in 2Q22 Might Establish the Role of Complement in Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Annexon, Inc.
Industry: Medical - Biomedical and Genetics
Interim HD data Indicate ANX005?s Robust Target Engagement in the CNS
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A